Comparison of the effects of amlodipine and cilnidipine on blood pressure, heart rate, proteinuria and lipid profile in hypertensive patients
Keywords:
Hypertension, Cilnidipine, Amlodipine, Diabetic, ProteinuricAbstract
Background: Hypertension is a widespread public health problem and a major risk factor. Amlodipine, a calcium channel blocker is frequently used in the treatment of hypertension. Since Amlodipine primarily L-type calcium channel blocker (CCB) and thus reduces blood pressure, it stimulates sympathetic nerve activity leading to reflex increase in heart rate. Cilnidipine, a new type of CCB which can inhibit L- type calcium channels but also N-type calcium channels. We compare the clinical effectiveness of Amlodipine and Cilnidipine on blood pressure, heart rate, proteinuria and lipid profile in hypertensive patients.
Methods: The study was a prospective, randomized, open label comparison, total ninety five patients were recruited for study in which 45 patients received 5-10mg Amlodipine and other 55 patients of same age groups received 10-20mg Cilnidipine. 15 patients in Amlodipine group and 18 patients in Cilnidipine group were diabetic, whereas 12 and 14 patients were proteinuric in Amlodipine and Cilnidipine group respectively.
Results: Both the groups were well matched in term of age, weight, clinical findings and laboratory values. Both the drug significantly reduced both systolic (SBP) and diastolic blood pressure (DSP). In the Amlodipine group the pulse rate (PR) after treatment tended to be higher than those before treatment. In the Cilnidipine group there was decrease in PR after treatment. Unlike Amlodipine, Cilnidipine decreased urinary protein excretion and in diabetic patients reduced serum triglyceride.
Conclusions: The study indicates that unlike Amlodipine, Cilnidipine which inhibits L-and N-type calcium channels will be useful for patients with hypertension and cardiovascular disease, diabetes mellitus or renal disease and proves to be a better alternative to existing calcium channel blockers.
References
Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008;51:742-8.
Giles TD. Hypertension is taking on a ‘new look’ Business briefing. US Cardiology 2006:1-4.
Fujii S, Kameyama K, Hosono M, Hyashi Y, Kitamure K. Effect of Cilnidipine, a novel dihydropyridine ca+² channel antagonist on N-type ca+² channel in rat dorsal root ganglion neuron. J Pharmacol Exp Ther 1997;280:1184-91.
Hirning ID, Fox AP, Mc Cleskey FW, et al. Dominant role of N-type ca+² in evoked release of nor- epinephrine from sympathetic neurons. Science 1998;239:57-61.
Minami J, Ishimitsu T, Kawano Y, Numabe A, Matsuoka H. Comparison of 24-hour blood pressure, heart rate and autonomic nerve activity in hypertensive patients treated with Cilnidipine or Nifedipine retard. J Cardiovasc Pharmacol 1998;32:331-6.
Takahara A. Cilnidipine: a new generation Ca²+ channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 2009;27:124-39.
De Champlain J, Karas M, Nguven P, et al. Different effect of nifedipine and amlodipine on circulatory catecholamine level in essential hypertensive patients. J Hypertens 1998;16:1357-69.
Hoshide S, Kario K, Ishikawa J, et al. Comparison of the effects of Cilnidipine and Amlodipine on ambulatory blood pressure. Hypertens Res 2005;28:1003-8.
Yamagishi T. Beneficial effect of Cilnidipine on morning hypertension and white- coat effect in patients with essential hypertension. Hypertens Res 2006;29:339-44.
Zhou X, Ono H, Ono Y, Frohlich ED. N- and L- type calcium channel antagonist improve glomerular dynamics, reserves severe nephrosclerosis and inhibits apoptosis and proliferation in an L-NAME/SHR model. J Hypertens 2002;20:993-1000.
Rose GW, Konnoy, Ikebukuroh, et al. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001;24:377-83.
Masuda T, Ogura MN, Moriya T, Takahira N, Matsumoto T, et al. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus. Cardiovasc Ther 2011;29:46-53.
Ahaneka JE, Sakata K, Urano T, et al. Infuence of baseline values on lipids, lipoproteins, and fibrolytic parameters during treatment of hypertension with Cilnidipine. Pharmacol Res 2000;41:79-82.
Ahaneku JE, Sakata K, Uranol T, et al. Effects of Cilnidipine on lipids, lipoproteins and fibrinolytic system in hypertensive patients. Drugs Exp Clin Res 2000,26:119-23.
Gillman MW, Kannel WB, Belanger A, Agostino RB. Influence of heart rate on mortality among person with hypertension: the Framingham Study. Am Heart J 1993;125:1148-54.
Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995,274:620-5.
Chobanian AV, Bakris GL, Black HR, et al: The seventh report of the Joint National Committee on prevention,detection,evaluation and treatment of high Blood Pressure: the JNCI report. JAMA 2003;289:2560-71.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
Sataka K, Shirotani M, Yoshida H, et al. Effects of Amlodipine and Cilnidipine on cardiac sympathetic nervous system and neuro hormonal status in essential hypertension. Hypertension 1999;33:1447-52.
Minami J, Ishimitsu T, Matsuoka H. Effects of Amlodipine and Nifedipine retard on autonomic nerve activity in hypertensive patients. Clin Exp Pharmacol Physiol 1998;25:572-6.
Morimoto S, Takeda K, Oguni A, et al. Reduction of white coat effect by Cilnidipine in essential hypertension. Am J Hypertens 2001;14:1053-7.
Razicka M, Leenen FH. Relevance of 24 h blood pressure profile and sympathetic activity for outcome on short versus long acting 1,4- dihydropyridines. Am J Hypertens 1996;9:86-94.
Vupputurti S, Batuman V, Bazzano LA. Effect of blood pressure on early decline in kidney function among hypertensive men. Hypertension 2003;42:144-9.
Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.
Zhou X, Ono H, Ono Y, Frohlich ED. N-and L-type calcium channel antagonist improve glomerular dynamics, reverse severe nephrosclerosis and inhibits apoptosis and proliferation in an L-NAME/SHR model. J Hypertens 2002;20:993-1000.
Kojima S, Shida M, Yokoyana H. Comparison between Cilnidipine and Amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004;27:379-85.
Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Takahashashi K. Antiproteinuric effect of the calcium channel blocker Cilnidipine added to rennin angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007;72:1543-9.
Masuda T, Ogura MN, Moriya T, Takahira N, Matsumoto T, et al. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus. Cardiovasc Ther 2011;29:46-53.
Ahaneku JE, Sakata K, Uranol T, et al. Effects of Cilnidipine on lipids, lipoproteins and fibrinolytic system in hypertensive patients. Drugs Exp Clin Res 2000;26:119-23.
